<DOC>
	<DOCNO>NCT00658970</DOCNO>
	<brief_summary>The purpose Phase 1 study determine safety tolerability KX2-391 cancer patient .</brief_summary>
	<brief_title>Evaluation KX2-391 Patients With Advanced Malignancies</brief_title>
	<detailed_description>The purpose first human study determine safety pharmacokinetics KX2-391 patient solid tumor lymphoma , refractory conventional cancer treatment . In addition , pharmacodynamics evaluate use biomarkers peripheral blood mononuclear cell tissue biopsy sample .</detailed_description>
	<criteria>Signed write informed consent Adults age 18 year age Confirmed advanced solid tumor lymphoma may metastatic unresectable standard curative palliative measure exist longer effective ; patient treat brain ocular metastasis also eligible ECOG performance status 02 Life expectancy least 14 week Adequate bone marrow reserve Adequate liver function demonstrate serum bilirubin , alanine aminotransferase ( ALT ) , aspartate transaminase ( AST ) alkaline phosphatase ( ALP ) Adequate renal function ( serum creatinine &lt; /= 1.5 x ULN calculate creatinine clearance &gt; 60 ml/min ) Normal coagulation profile ( PT/INR aPTT within institutional normal limit ) give consent tumor biopsy , within 1 week prior procedure . Negative pregnancy test female Screening , preferably do within 1 week Day 1 dosing ( applicable patient bilateral oophorectomy and/or hysterectomy ) Willing abstain sexual activity practice physical barrier contraception 28 day Day 1 dose 6 month last dose patient Signed write informed consent tumor biopsy additional 10 subject dose MTD accessible tumor Unresolved toxicity high Grade 1 severity previous anticancer treatment investigational agent Receiving receive investigational agent systemic anticancer agent within 14 day Day 1 dose 28 day agent unknown elimination halflives halflives great 50 hour Received extensive radiation therapy include sternum , pelvis , scapula , vertebra skull , &lt; /= 4 week low dose palliative radiation therapy limit limbs &lt; /= 1 week prior start study drug , recover side effect therapy Currently take hormone ( i.e. , estrogen contraceptive , hormone replacement , antiestrogen ) , antiplatelet agent anticoagulant , e.g . coumadin , except prophylactic dos anticoagulant indwell venous catheter Use strong inhibitor inducer cytochrome P450 3A4 enzymes 2 week 5 halflives prior Day 1 dose study ( refer Appendix 3 ) Pregnant breastfeed Major surgery within 4 week prior Day 1 dose Major surgery upper gastrointestinal tract , inflammatory bowel disease , malabsorption syndrome medical condition may interfere oral absorption Signs symptom end organ failure , major chronic illness cancer , severe concomitant condition , opinion investigator , make undesirable subject participate study could jeopardize compliance protocol History angina pectoris , coronary artery disease cerebrovascular accident , transient ischemic attack cardiac arrhythmia require medical therapy Evidence hepatitis B C , human immunodeficiency ( HIV ) infection , coagulation disorder , hemolytic condition , e.g . sickle cell anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Open label</keyword>
	<keyword>Dose escalation</keyword>
</DOC>